A Phase II Study of Niraparib With Dostarlimab Therapy as Neoadjuvant Treatment for Patients With BRCA-mutated Breast Cancer
Latest Information Update: 30 May 2024
At a glance
- Drugs Dostarlimab (Primary) ; Niraparib (Primary)
- Indications Advanced breast cancer; Early breast cancer; HER2 negative breast cancer; Male breast cancer
- Focus Therapeutic Use
- 28 May 2024 Planned primary completion date changed from 17 Jul 2024 to 17 Jul 2025.
- 31 Dec 2020 Status changed from not yet recruiting to recruiting.
- 13 Oct 2020 New trial record